ArticleAAPS PharmSciTech2026
Efficient Loading of Rabeprazole Sodium via Porous Anion Exchange Resin for Enteric Delivery.
Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rabeprazole sodium (RAB), a widely used proton pump inhibitor for treating gastroesophageal reflux disease (GERD), faces limitations in administration to pediatric and dysphagic patients due to the swallowing difficulties posed by conventional oral solid formulations. To overcome these issues, this study developed a pediatric-friendly oral RAB formulation based on a novel anion exchange resin (AER). The synthesized AER exhibited a regular spherical morphology, high porosity, and uniform particle size distribution. RAB was efficiently loaded via ion exchange to form RAB-loaded AER complexes (RAB@AER), achieving a 1.63-fold higher drug loading capacity than that of conventional resins. RAB@AER were subsequently coated with Eudragit L100 using an emulsion-solvent evaporation method, yielding microcapsules consisting of RAB-loaded AER coated by L100 (RAB@AER@L100). In vitro release studies confirmed the enteric protection of the microcapsules, with negligible drug release in acidic medium (pH 1.2) and sustained release under neutral conditions (pH 6.8). The RAB@AER@L100 enteric suspension was developed by blending the microcapsules with suitable excipients, requiring reconstitution with water before oral administration. Pharmacokinetic evaluation in rats revealed that the reconstituted suspension accelerated drug absorption (T
Indexed as
Identifiers
42010084What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.